Dublin, Oct. 31, 2022 (GLOBE NEWSWIRE) — The “Asia Pacific Proton Therapy Market Size, Share and Trend Analysis Report by Product Type, Indication (CNS Cancer, Prostate Cancer, Head & Neck Cancer, Breast Cancer & Others), By End User, By Country & Growth Forecast, 2022 – 2028″ has been added to from ResearchAndMarkets.com offer.
The Asia-Pacific proton therapy market is expected to witness a market growth of 13.3% CAGR during the forecast period (2022-2028).
High-quality imaging for daily tumor contour assessment, treatment planning software that shows dose distributions in 3D, and a variety of system configurations, such as multiple treatment rooms connected to an accelerator, are all characteristics of modern proton systems. The number of hospitals offering proton therapy continues to grow, partly because of these technological advances and partly because of the growing body of clinical data related to proton therapy.
A method called FLASH radiation, which uses extremely high dose rates for photon and proton treatments, is currently under development. If used in a clinical setting, it could reduce the number of treatments needed to just one to three one-second sessions, further minimizing side effects.
Some of the major factors influencing the regional market include an increase in the prevalence of cancer, an increase in government measures to develop healthcare infrastructure, and an increase in the number of people prone to various chronic diseases. Moreover, the development and approval of products for proton therapy could benefit the market growth in advanced countries like Japan. Growing healthcare infrastructure and improved government initiatives are expected to enable regional market players to increase their offerings and get the highest revenue share possible.
The Chinese market led the Asia-Pacific proton therapy market by country in 2021 and is expected to continue to be a dominant market through 2028; thereby reaching a market value of $74,530.9 thousand by 2028. The Japanese market is poised to witness a CAGR of 12.6% during (2022 – 2028). Moreover, the Indian market is witnessing a CAGR of 14% during (2022 – 2028).
Based on product type, the market is segmented into accelerator, beam delivery system, beam transport system, nozzle and image viewers, and patient positioning system. Based on the indication, the market is segmented into CNS cancer, prostate cancer, head and neck cancer, breast cancer and others. Based on end user, the market is segmented into hospitals, proton therapy centers and others. Based on country, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of major market players. Key companies profiled in the report are Toshiba Corporation, Siemens Healthineers AG (Siemens AG), Ion Beam Applications SA, Hitachi, Ltd., Mirion Technologies, Inc., Mevion Medical Systems, Inc., Provision Healthcare, Sumitomo Corporation, and Optivus Proton Therapy. , Inc.
Scope of the study
Market Segments Covered in the Report:
By product type
- beam delivery system
- Beam transport system
- Nozzle and image viewers
- Patient positioning system
- CNS cancer
- Prostate cancer
- Head and neck cancer
- Breast cancer
Per end user
- Proton therapy centers
- South Korea
- Rest of Asia-Pacific
Unique Publisher Offers
- Comprehensive coverage
- The largest number of tables and figures on the market
- Subscription model available
- Best price guaranteed
- After-sales research support provided with 10% free customization
Main topics covered:
Chapter 1. Market Scope and Methodology
Chapter 2. Market Overview
Chapter 3. Strategies deployed in the Proton Therapy Market
Chapter 4. Asia-Pacific Proton Therapy Market by Product Type
Chapter 5. Asia-Pacific Proton Therapy Market by Indication
Chapter 6. Asia Pacific Proton Therapy Market by End User
Chapter 7. Asia-Pacific Proton Therapy Market by Country
Chapter 8. Business Profiles
- Toshiba Company
- Siemens Healthineers AG (Siemens AG)
- Ion Beam Applications SA
- Hitachi, Ltd.
- Mirion Technologies, Inc.
- Mevision Medical Systems, Inc.
- Provide health care
- Sumitomo Company
- Optivus Proton Therapy, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/1agqfz